Nomura Holdings’s Keros Therapeutics KROS Stock Holding History

Nomura Holdings’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-156,753	Closed	-$3.19M	–	1932
2025 Q4	$3.19M	Buy	+156,753	New	+$2.75M	﹤0.01%	936

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Nomura Holdings's KROS Position: Q1 2026 in Review

Nomura Holdings sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 156,753 shares — an estimated $3.19M sold.

Nomura Holdings first reported a position in KROS in Q4 2025 and held it in 1 quarter. The position peaked at $3.19M in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

Nomura Holdings reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
Nomura Holdings sold 156,753 Keros Therapeutics shares in Q1 2026, an estimated $3.19M.
Nomura Holdings first reported a position in Keros Therapeutics in Q4 2025 and held it in 1 quarter.
Nomura Holdings's Keros Therapeutics position peaked at $3.19M in Q4 2025.
151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.